Literature DB >> 8876932

Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats.

C Shudo1, Y Masuda, H Sugita, T Tamura, S Furukawa, K Hayashi, H Hirata, K Shikada, S Tanaka, K Tomita.   

Abstract

Previous studies have shown that antihypertensive drugs attenuate the progression of proteinuria by their treatments from young age, but few have examined their effects on impaired renal function in older age. In the present study the calcium antagonists efonidipine ((+/-)-2-[benzyl (phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3, 2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxyla te hydrochloride ethanol, CAS 111011-76-8, NZ-105) and nicardipine, and an angiotensin-converting enzyme inhibitor, captopril, were examined for their effects on heavy proteinuria in aged spontaneously hypertensive rats (SHR). Efonidipine (20 mg/kg), nicardipine (20 mg/kg) and captopril (30 mg/kg) were orally administered once a day for 4 weeks. The urinary protein excretion (UproE) increased with age (54.9 mg/kg/day at 24 weeks of age to 170.8 mg/kg/day at 36 weeks). The increased UproE was significantly suppressed by daily administration of efonidipine or captopril as compared to that in the non drug treated control group. The UproE in the nicardipine group was maintained at a slightly lower level than in the control. The histological examination showed that the damages of the kidneys were slightly suppressed by efonidipine and captopril. These findings indicate that efonidipine as well as captopril reduce proteinuria in aged SHR and the effect was stronger than that of nicardipine. This beneficial effect of efonidipine on proteinuria suggests its usefulness in antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876932

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  1 in total

1.  T-type calcium channel blocker attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis by activating the Nrf2 antioxidant pathway.

Authors:  Sungjin Chung; Soojeong Kim; Minyoung Kim; Eun Sil Koh; Hye Eun Yoon; Ho-Shik Kim; Cheol Whee Park; Yoon Sik Chang; Seok Joon Shin
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.